Contribute Try STAT+ Today

Hello, everyone, and how are you this fine, sunny morning? Here on the Pharmalot campus, the birds are chirping, the chipmunks are scurrying, and a cool breeze is wafting by. What could be better? As you might guess, this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day, and drop us a line if you hear something saucy. …

In hopes of alleviating potential drug shortages and other issues wrought by Covid-19, the Food and Drug Administration drastically rolled back oversight of compounding pharmacies — a swift and sweeping relaxing of the rules that were put in place after a fungal meningitis outbreak traced to one such center killed more than 60 people, STAT says. Public health experts say there is merit to relaxing the rules amid the pandemic, but caution there is no reason to make the changes permanent. Compounders are gearing up for a fight to do just that.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy